ATRC stock forecast, quote, news & analysis
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors... Show more
AtriCure (ATRC) Stock Analysis: Expanding Margins and Afib Device Momentum Keep Shares in a Tight Range
Key Takeaways
- AtriCure shares have been roughly flat over the past 30 days, holding near the $59 level after a late-September advance and a subsequent pullback.
- The company is delivering double-digit revenue growth, with second-quarter 2026 revenue rising 12.8% year over year to $153.6 million.
- Profitability is strengthening quickly: adjusted EBITDA climbed 78% year over year in the second quarter, and the company returned to GAAP net income.
- Growth is being driven by newer products, including the AtriClip FLEX-Mini, cryoSPHERE MAX probe, and EnCompass clamp, alongside expanding pain-management adoption.
- Two large clinical trials, LeAAPS and BoxX-NoAF, represent longer-term catalysts that management positions as opportunities to expand the addressable market.
- Investors can review additional Price Targets, Earnings, and Forecast data on dedicated pages for a deeper look at the company's outlook.
- Readers interested in automated strategies can explore Trending AI Robots to see curated, top-performing trading bots across thousands of tickers.
Current Market Snapshot
AtriCure, Inc. (NASDAQ: ATRC) has traded in a relatively narrow band over the trailing 30 days. After climbing through September and reaching levels near $60, the stock pulled back in early October before stabilizing and recovering toward $59. The net 30-day change is modest, keeping shares within a consolidation range rather than showing a decisive directional breakout.
Sentiment around the stock remains constructive, supported by consistent revenue growth, improving profitability, and positive cash generation. Investors continue to weigh near-term margin progress against a premium valuation and competitive dynamics in the electrophysiology and appendage-management markets.
AtriCure (ATRC) Business Overview and Competitive Position
AtriCure is a medical device company focused on surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company's Isolator Synergy Ablation System was the first device to receive FDA approval for the treatment of persistent Afib, while its AtriClip LAA exclusion products are among the most widely sold LAA management devices worldwide.
The business is organized around several product franchises: open ablation, minimally invasive ablation, appendage management, and pain management. Recent growth has been concentrated in appendage management and pain management, led by the AtriClip FLEX-Mini device, the cryoSPHERE MAX probe, and the EnCompass clamp. AtriCure's Hybrid AF Therapy addresses long-standing persistent Afib through a minimally invasive procedure, and the company invests heavily in clinical evidence to support guideline changes and reimbursement expansion.
Recent Developments Driving ATRC
AtriCure's most recent quarterly report highlighted a meaningful step-up in profitability. Second-quarter 2026 revenue reached $153.6 million, up 12.8% year over year, with net income of $9.0 million and adjusted EBITDA of $27.3 million, a 78% increase from the prior-year period. The company also generated $21.6 million in cash during the quarter and raised its full-year adjusted EBITDA guidance to a range of $85 million to $89 million.
Product innovation continues to underpin the growth narrative. Adoption of the AtriClip FLEX-Mini in open appendage management and the cryoSPHERE MAX probe in pain management has been strong, while the company received CE Mark approval under EU MDR for the AtriClip FLEX-Mini and PRO-Mini devices, supporting a planned European launch. On the clinical front, AtriCure is advancing two large randomized trials, LeAAPS and BoxX-NoAF, which management views as potential drivers of expanded labeling and broader market adoption over time.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies from a broader library of hundreds of AI-driven bots that trade thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving users a filtered view of strategies that are currently standing out. The bots vary widely in trading strategy, timeframe, and performance metrics, allowing users to compare approaches that suit different risk profiles and objectives. The page is designed to help traders and investors evaluate AI-powered automation alongside their own research and market analysis.
2026 Outlook and What Investors Should Watch
AtriCure has reiterated full-year 2026 revenue guidance of approximately $602 million to $610 million, reflecting growth of roughly 12% to 14%, and now expects adjusted EBITDA of $85 million to $89 million. Investors will be watching whether the company sustains its margin expansion while continuing to grow its appendage-management and pain-management franchises.
Key areas to monitor include the pace of adoption for newly launched products across the U.S. and international markets, progress in the LeAAPS and BoxX-NoAF clinical trials, and the competitive landscape in appendage management and pulsed field ablation. International reimbursement conditions, particularly in the U.K. and Germany, and foreign-exchange effects also remain relevant variables. As with any growth-stage medical device company, execution against guidance and the timing of clinical milestones are likely to be important drivers of sentiment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ATRC's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ATRC turned positive on October 23, 2026. Looking at past instances where ATRC's MACD turned positive, the stock continued to rise in 38 of 46 cases over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ATRC as a result. In 62 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
Following a +1.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATRC advanced for three days, in 215 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
ATRC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 157 of 222 cases where ATRC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Bearish Trend Analysis
The 10-day RSI Indicator for ATRC moved out of overbought territory on September 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 23 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATRC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ATRC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.808) is normal, around the industry mean (4.989). ATRC's P/E Ratio (268.045) is considerably higher than the industry average of (37.210). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.869) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of surgical and medical instruments
Industry PharmaceuticalsOther